dengu
viru
serotyp
transmit
mosquito
caus
frequent
arbovir
infect
world
result
million
case
death
annual
vaccin
antivir
drug
current
avail
human
use
compound
contain
quinolin
scaffold
shown
inhibit
flaviviru
proteas
good
potenc
studi
screen
quinolin
deriv
known
antimalari
drug
inhibit
west
nile
viru
wnv
replic
use
correspond
replicon
express
cellbas
assay
amodiaquin
aq
one
drug
inhibit
infect
measur
plaqu
assay
ec
ec
valu
respect
rna
replic
measur
renilla
luciferas
report
assay
ec
valu
replicon
express
cell
cytotox
concentr
cc
cell
replic
inhibit
confirm
plaqu
assay
extracellular
virion
well
qrtpcr
intracellular
extracellular
viral
rna
level
aq
stabl
least
h
minor
inhibitori
effect
entri
translat
postrepl
stage
viral
life
cycl
denv
proteas
rnadepend
rna
polymeras
seem
target
aq
phydroxyanilino
diethylaminomethyl
moieti
import
aq
inhibit
replic
infect
result
support
aq
promis
candid
antiflavivir
therapi
repurpos
antimalari
dengu
antivir
chloroquin
primaquin
stabl
replicon
cell
line
dengu
west
nile
virus
inhibit
dengu
viru
replic
infect
amodiaquin
therapeut
index
antivir
re
dengu
viru
denv
mosquitoborn
member
flaviviru
genu
flavivirida
famili
positivestrand
rna
genom
four
serotyp
denv
caus
million
infect
annual
bhatt
et
al
mitka
secondari
infect
differ
denv
serotyp
could
lead
sever
clinic
manifest
due
antibodi
depend
enhanc
current
vaccin
antivir
drug
avail
combat
dengu
diseas
denv
rna
encod
singl
polyprotein
process
yield
structur
protein
capsid
c
precursor
membran
prm
envelop
e
nonstructur
ns
protein
lindenbach
et
al
viral
rna
replic
cisact
rna
element
encod
within
region
utr
code
region
within
ntermin
capsid
protein
ctermin
envelop
well
ns
protein
suffici
excel
review
see
lindenbach
et
al
paranjap
harri
villordo
gamarnik
westaway
et
al
studi
cisact
rna
element
transact
viral
host
factor
requir
replic
subgenom
replicon
construct
sever
flavivirus
kunjin
khromykh
westaway
wnv
alcarazestrada
et
al
shi
et
al
yfv
jone
et
al
alvarez
et
al
jone
et
al
manzano
et
al
ng
et
al
alcarazestrada
et
al
stabl
replicon
express
cell
line
use
screen
antivir
compound
potenti
inhibitor
viral
replic
review
see
nobl
et
al
sampath
padmanabhan
sinc
flaviviru
rna
encod
sever
enzym
play
import
role
viru
life
cycl
vitro
assay
develop
screen
antivir
compound
exampl
vitro
assay
twocompon
viral
proteas
lai
et
al
mueller
et
al
yusof
et
al
methyltransferas
catalyz
ntermin
domain
dong
et
al
egloff
et
al
ray
et
al
rnadepend
rna
polymeras
rdrp
catalyz
ctermin
domain
ackermann
padmanabhan
niyomrattanakit
et
al
niyomrattanakit
et
al
assay
use
identifi
inhibitor
proteas
ezgimen
et
al
johnston
et
al
lai
et
al
methyltransferas
review
dong
et
al
rdrp
niyomrattanakit
et
al
wu
et
al
zou
et
al
small
molecul
compound
use
vitro
proteas
report
replicationbas
assay
identifi
compound
contain
scaffold
potent
inhibitor
wnv
proteas
ezgimen
et
al
lai
et
al
mueller
et
al
studi
sought
investig
whether
quinolin
deriv
alreadi
known
fdaapprov
antimalari
drug
chloroquin
amodiaquin
primaquin
could
inhibit
viral
proteas
well
replic
denv
wnv
amodiaquin
dihydrochlorid
dihydr
amino
diethylamino
methyl
phenol
aq
catalog
obtain
sigma
aldrich
st
loui
mo
quinolin
deriv
obtain
nation
cancer
institutedevelopment
therapeut
program
ncidtp
mg
quantiti
compound
dissolv
dmso
unless
otherwis
state
make
mm
stock
solut
store
aliquot
experi
aqueou
solut
aq
use
indic
construct
renilla
luciferas
report
replicon
describ
previous
manzano
et
al
construct
express
plasmid
encod
renilla
luciferas
rluc
report
replicon
contain
select
marker
neomycin
resist
gene
neo
r
stabl
cell
line
describ
supplementari
method
fig
tabl
cell
express
replicon
vero
cell
express
alcarazestrada
et
al
wnv
verownv
alcarazestrada
et
al
replicon
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
nonessenti
amino
acid
mediatech
manassa
va
iuml
penicillin
streptomycin
penicillinstreptomycin
fisher
scientif
pittsburgh
pa
cell
well
seed
black
microtit
plate
greiner
bioon
monro
nc
incub
h
co
follow
addit
compound
dmso
final
concentr
indic
dmso
alon
use
noinhibitor
control
luciferas
activ
inhibit
cell
incub
indic
time
point
exampl
h
experi
shown
tabl
h
experi
shown
fig
cell
lyse
renilla
luciferas
rluc
activ
measur
accord
manufactur
protocol
promega
madison
wi
usa
use
centro
lb
luminomet
berthold
technolog
oak
ridg
tn
data
report
percent
inhibit
rel
dmso
inhibit
mycophenol
acid
inhibit
control
select
compound
show
greater
inhibit
analyz
determin
effect
concentr
inhibit
obtain
ec
calcul
ec
valu
compound
serial
dilut
final
indic
concentr
experi
shown
tabl
expand
serial
dilut
describ
fig
legend
activ
valu
variou
concentr
compound
plot
nonlinear
regress
use
graphpad
prism
softwar
la
jolla
ca
cytotox
aq
evalu
two
method
first
vero
cell
treat
compound
parallel
replicon
cell
method
use
evalu
cc
h
treatment
select
compound
cell
viabil
assess
measur
atp
level
use
celltiterglo
luminesc
cell
viabil
assay
kit
promega
accord
manufactur
protocol
briefli
vero
cell
cellswel
seed
plate
cell
incub
h
compound
ad
concentr
replicon
assay
describ
tabl
figur
legend
celltiterglo
substrat
ad
accord
manufactur
protocol
plate
read
luminomet
data
analyz
determin
cell
viabil
cc
valu
use
graphpad
prism
softwar
second
method
viabil
replicon
express
cell
variou
concentr
compound
measur
sampl
use
luciferas
activ
measur
use
cell
count
dojindo
molecular
technolog
rockvil
md
h
lysi
rluc
activ
measur
colorimetr
assay
util
highli
solubl
noncytotox
tetrazolium
salt
ad
experiment
cultur
incub
h
plate
read
use
concert
triad
spectrophotomet
dynex
chantilli
va
cell
wash
lyse
rluc
activ
measur
describ
cc
valu
calcul
use
graphpad
prism
softwar
cell
seed
plate
cellswel
incub
overnight
cell
infect
multipl
infect
moi
indic
infect
cell
wash
pb
incub
ml
mem
supplement
fb
iuml
streptomycin
refer
mainten
medium
aq
indic
concentr
ad
cell
incub
variou
time
point
indic
dmso
nocompound
control
infect
mockinfect
control
use
medium
alon
infect
includ
supernat
collect
time
point
experi
viru
titer
determin
plaqu
assay
cell
seed
cellswel
plate
cellswel
plate
incub
reach
confluenc
cell
infect
supernat
collect
experi
aq
treatment
cell
wash
pb
incub
ml
overlay
medium
mainten
medium
contain
methylcellulos
plate
incub
day
co
plaqu
becam
visual
appar
microscopi
cell
fix
stain
formaldehyd
isopropanol
crystal
violet
min
number
plaqu
form
unit
pfu
per
ml
determin
cell
seed
describ
aq
indic
concentr
dmso
ad
moi
infect
cell
adsorpt
andor
postinfect
supernat
collect
indic
time
point
postinfect
plaqu
assay
intracellular
rna
extract
infect
cell
treatment
trizol
reagent
invitrogen
life
grand
island
ny
accord
manufactur
protocol
total
rna
quantifi
use
nanodrop
thermo
fisher
scientif
waltham
adjust
revers
transcript
iscript
cdna
synthesi
biorad
hercul
ca
quantit
rtpcr
qpcr
perform
previous
describ
manzano
et
al
briefli
region
viral
rna
encod
gene
amplifi
use
forward
revers
primer
tabl
glyceraldehyd
dehydrogenas
gene
gapdh
chosen
housekeep
refer
rna
amplifi
pcr
use
forward
revers
primer
tabl
viral
rna
copi
number
calcul
aqtreat
cell
rel
aquntr
cell
dmso
alon
supernat
experi
also
collect
store
aliquot
ml
use
supernat
concentr
millipor
billerica
viral
rna
extract
qiaamp
viral
rna
mini
kit
qiagen
valencia
ca
prior
cdna
synthesi
describ
protocol
adapt
stahlabeek
et
al
stahlabeek
et
al
cell
grown
plate
cellswel
infect
moi
mainten
medium
cell
wash
pb
incub
ml
mainten
medium
aq
indic
concentr
ad
cell
incub
supernat
sampl
indic
store
plaqu
assay
protocol
adapt
schmidt
et
al
schmidt
et
al
cell
grown
plate
treat
aq
one
three
way
aq
moi
dilut
mainten
medium
incub
min
ad
cell
preincub
mixtur
aq
ad
cell
directli
coinfect
cell
infect
mockinfect
dmso
contain
medium
h
wash
incub
medium
contain
aq
postinfect
supernat
collect
h
postinfect
plaqu
assay
protocol
adapt
wang
et
al
cell
grown
plate
infect
moi
aq
dmso
alon
ad
cell
differ
time
postinfect
indic
supernat
collect
h
postinfect
determin
titer
plaqu
assay
addit
perform
time
addit
assay
slight
modif
studi
effect
aq
viral
translat
collect
sampl
indic
within
first
h
addit
aq
dmso
moi
supernat
collect
h
postinfect
plaqu
assay
antimalari
quinolin
compound
screen
use
verownv
replicon
cell
tabl
fig
antimalari
compound
test
final
concentr
includ
deriv
chloroquin
cq
chloroquin
ethyl
phenyl
mustard
chloroquin
mustard
chloroquin
pamoat
chloroquin
sulfat
amodiaquin
aq
deriv
apoquinin
primaquin
quinin
quinin
hydrobromid
hydrat
acridin
deriv
quinacrin
mustard
aq
diethylaminomethyl
group
show
inhibit
wnv
replicon
replic
respect
two
chloroquin
deriv
one
acridin
deriv
compound
tabl
mustard
group
show
inhibit
verownv
replicon
replic
fig
deriv
contain
common
side
chain
dichloroethylamino
group
also
known
mustard
group
howev
compound
low
ti
valu
rang
inhibit
verownv
replicon
replic
due
cytotox
vero
cell
tabl
howev
compound
dichloroethylamino
side
chain
known
cytotox
potenti
form
skinblist
key
welsh
et
al
therefor
compound
pursu
base
result
primari
screen
fig
eight
aq
deriv
tabl
obtain
analysi
show
strong
inhibit
wnv
replicon
replic
fig
howev
none
aqd
show
higher
ti
aq
due
cytotox
low
cc
valu
tabl
result
show
compound
lack
diethylamino
methyl
group
adjac
phenol
oh
moieti
fail
inhibit
replicon
replic
ec
valu
describ
section
ec
cc
compound
test
verownv
replicon
cell
therapeut
indic
ti
calcul
ti
valu
aq
replicon
cell
ec
fig
wherea
cell
ti
aq
fig
verownv
cell
fig
due
cytotox
aq
vero
cell
verifi
aq
interfer
rluc
enzym
activ
ad
replicon
cell
lysat
fig
next
analyz
effect
aq
intracellular
extracellular
rna
level
well
viru
infect
cell
viral
replic
quantifi
qrtpcr
viru
infect
plaqu
assay
cell
treat
fix
concentr
aq
infect
cell
incub
h
fig
result
show
signific
differ
p
aqtreat
untreat
group
result
indic
aq
effect
inhibit
replic
reduc
level
intracellular
extracellular
rna
viru
infect
measur
pfuml
supernat
aquntr
aq
treat
cell
plaqu
assay
also
show
signific
reduct
upon
treatment
drug
fig
taken
togeth
result
support
conclus
result
use
replicon
cell
fig
next
sought
determin
ec
ec
valu
aqmedi
inhibit
extracellular
releas
infect
cell
end
cell
infect
treat
aq
variou
concentr
indic
supernat
collect
h
moi
h
moi
postinfect
analyz
plaqu
assay
viru
titer
variou
concentr
aq
plot
use
graphpad
prism
softwar
ec
valu
moi
graphpad
plot
shown
ec
valu
moi
well
moi
independ
experi
shown
fig
result
thu
far
indic
aq
inhibit
replic
stabl
repliconexpress
cell
well
viru
titer
rna
copi
number
infect
cell
shown
plaqu
assay
qrtpcr
subsequ
experi
perform
cell
infect
determin
stage
viru
life
cycl
target
aq
first
time
cours
infect
absenc
presenc
differ
concentr
aq
fig
aq
ad
infect
cell
adsorpt
compound
present
throughout
durat
experi
h
postinfect
shown
fig
mockinfect
control
cell
dmso
alon
infect
titer
gradual
increas
time
howev
aqtreat
cell
viru
titer
pfuml
reduc
significantli
dosedepend
manner
p
fig
plaqu
format
reduc
observ
aqmedi
inhibit
increas
time
indic
aq
stabl
least
h
postinfect
analyz
aq
effect
viral
entri
aq
variou
concentr
incub
moi
monolay
h
adsorpt
period
overlay
medium
absenc
drug
ad
incub
day
describ
materi
method
data
obtain
experi
refer
direct
plaqu
assay
fig
stippl
bar
concurr
viru
supernat
collect
cell
infect
presenc
dmso
aq
present
h
postinfect
also
use
plaqu
assay
refer
indirect
plaqu
assay
viru
titer
determin
fig
open
bar
viru
titer
indirect
plaqu
assay
fig
open
bar
show
signific
inhibit
infect
aq
similar
result
shown
fig
b
howev
direct
plaqu
assay
sinc
aq
present
adsorpt
plaqu
titer
aq
significantli
differ
titer
dmso
control
fig
stippl
bar
result
indic
aq
inhibit
adsorpt
howev
viru
titer
reduc
treat
aq
respect
adsorpt
fig
stippl
bar
result
indic
inhibit
entri
requir
higher
concentr
aq
requir
inhibit
infect
ad
postinfect
confirm
aq
optim
inhibitori
effect
replic
ad
postinfect
period
expand
order
addit
aq
variou
time
point
three
differ
way
follow
mixtur
aq
moi
incub
min
prior
addit
cell
aq
moi
simultan
ad
cell
case
adsorpt
cell
wash
incub
mainten
medium
absenc
aq
aq
ad
cell
postadsorpt
present
throughout
postinfect
period
h
supernat
collect
h
postinfect
plaqu
assay
fig
result
indic
inhibit
infect
aq
maximum
reduct
plaqu
titer
dmso
control
h
postinfect
fig
stripe
bar
result
indic
major
step
inhibit
infect
aq
postentri
fusion
event
possibl
viral
translat
replic
assembl
viru
next
pinpoint
postinfect
stage
inhibit
precis
ad
aq
infect
cell
moi
variou
time
point
postinfect
indic
supernat
collect
h
postinfect
analyz
timedepend
plaqu
reduct
plaqu
reduct
found
even
drug
ad
late
h
postinfect
fig
h
postinfect
later
time
point
drug
lost
inhibitori
effect
investig
effect
aq
within
first
h
postinfect
examin
whether
aq
translat
inhibitor
similar
compound
benzomorphan
core
structur
result
indic
addit
aq
h
inhibit
infect
steadili
fig
even
ad
h
postinfect
fig
beyond
steadi
increas
titer
loss
inhibit
suggest
aq
could
inhibit
earli
event
includ
translat
viral
rna
templat
releas
endosom
event
prior
assembl
viral
rna
replicas
complex
onset
viral
rna
replic
fig
e
f
analysi
aq
deriv
use
replicon
cell
compound
lack
diethylaminomethyl
group
fail
inhibit
replicon
replic
ec
valu
tabl
tabl
least
higher
aq
chose
studi
use
infect
assay
variou
concentr
ad
infect
cell
moi
h
incub
supernat
collect
viru
titer
determin
plaqu
assay
result
show
ec
fig
fold
higher
compar
aq
ec
thu
modest
potenc
inhibit
replicon
replic
viral
infect
result
indic
diethylaminomethyl
group
key
chemic
structur
moieti
aq
contribut
inhibit
replic
infect
next
sought
investig
effect
cq
anoth
fdaapprov
antimalari
drug
deriv
fig
replic
cell
infect
moi
treat
cq
variou
concentr
viru
titer
supernat
determin
plaqu
assay
shown
fig
cq
inhibit
replic
cell
dosedepend
manner
although
inhibit
replicon
replic
fig
result
suggest
inhibit
cq
either
earli
stage
viru
entri
late
stage
viru
assembl
infecti
particl
find
support
notion
aq
target
factor
function
viral
replic
factor
could
either
viral
host
origin
first
investig
whether
aq
could
inhibitor
viral
proteas
activ
methyltransferas
rnadepend
rna
polymeras
activ
use
establish
vitro
biochem
assay
first
test
effect
aq
proteas
use
fluorescencebas
vitro
proteas
assay
lai
et
al
li
et
al
yusof
et
al
valu
aq
inhibit
proteas
fig
aq
effect
data
shown
henc
viral
proteas
like
target
aq
next
investig
whether
methyltransferas
activ
ntermin
domain
could
target
aq
ntermin
domain
activ
methyl
form
type
cap
dong
et
al
ray
et
al
fulllength
fl
twofold
effici
format
type
cap
data
shown
therefor
use
fl
vitro
assay
test
effect
aq
result
indic
aq
inhibit
format
type
cap
fl
mm
fig
next
examin
whether
rna
synthesi
catalyz
rdrp
enzym
might
target
aq
posit
neg
strand
rna
use
templat
vitro
rdrp
assay
presenc
aq
min
inhibit
rdrp
activ
aq
positivestrand
rna
synthesi
inhibit
observ
negativestrand
synthesi
fig
suggest
rdrp
like
target
aq
endow
atpdepend
rna
helicas
activ
benarroch
et
al
li
et
al
shiryaev
et
al
yon
et
al
attempt
use
fluorescencebas
assay
boguszewskachachulska
et
al
frick
et
al
lam
et
al
rna
helicas
partial
doublestrand
oligodeoxynucleotid
use
substrat
rna
helicas
studi
efficaci
amodiaquin
one
strand
substrat
label
fluorophor
fluorescein
black
hole
quencher
fluoresc
absenc
incub
helicas
releas
fluoresceinlabel
strand
timedepend
manner
although
assay
success
measur
helicas
activ
amodiaquin
interf
assay
due
bind
substrat
report
previous
oneil
et
al
data
shown
amodiaquin
aq
synthes
addit
group
chloroquin
cq
aq
proven
effect
chloroquineresist
strain
review
oneil
et
al
drug
later
withdrawn
longterm
antimalari
prophylaxi
due
rare
seriou
side
effect
agranulocytosi
hepatotox
review
olliaro
mussano
cochran
systemat
review
howev
support
use
aq
treatment
uncompl
malaria
besid
advers
drug
reaction
studi
found
signific
differ
among
cq
aq
sulfadoxinepyrimethamin
antimalari
review
olliaro
mussano
impact
enforc
modifi
recommend
aq
becam
option
treatment
uncompl
malaria
review
olliaro
mussano
aq
regimen
antimalari
treatment
three
day
mgday
adult
pharmacogenet
studi
discov
genet
trait
patient
popul
suscept
advers
effect
hepatotox
due
aq
link
polymorph
gene
one
cytochrom
genet
variant
gene
report
respons
defect
metabol
result
slow
clearanc
aq
review
kerb
et
al
genotyp
record
african
caucasian
popul
frequenc
respect
doseadjust
aq
increas
safeti
precaut
requir
treatment
patient
polymorph
order
prevent
intox
given
antidengu
efficaci
shown
studi
aq
like
becom
power
candid
treatment
denv
infect
patient
studi
mode
inhibit
replic
infect
aq
investig
potenti
target
aq
use
vitro
enzym
assay
timecours
analysi
suggest
drug
stabl
reproduc
inhibit
infect
h
postinfect
also
learn
viral
entri
intern
partial
inhibit
drug
major
effect
drug
occur
later
stage
viral
life
cycl
h
postinfect
effect
aq
earli
stage
adsorptionentri
would
absent
repliconexpress
cell
henc
ec
valu
higher
tabl
fig
aq
also
ineffect
inhibit
replic
alreadi
establish
seen
time
addit
assay
previou
studi
show
replic
start
h
postinfect
suggest
rapid
increas
intracellular
rna
level
cell
quantifi
qrtpcr
shrivastava
et
al
studi
shown
drug
less
effect
ad
later
h
postinfect
measur
viral
infect
fig
base
result
conclud
earli
stage
viru
life
cycl
includ
translat
assembl
viral
replicas
complex
initi
viral
rna
replic
could
target
aq
report
aq
potent
inhibitor
histaminenmethyltransferas
ec
ki
nm
horton
et
al
crystal
structur
two
molecul
aq
complex
histaminenmethyltransferas
sam
bind
pocket
nearbi
outer
pocket
solv
horton
et
al
anoth
crystal
structur
aq
complex
phosphoethanolamin
methyltransferas
plasmodium
falciparum
sam
bind
pocket
also
report
howev
result
exclud
methyltransferas
rdrp
activ
well
proteas
activ
target
aq
viral
replic
requir
viral
host
factor
review
bollati
et
al
ivanyinagi
darlix
sampath
padmanabhan
possibl
aq
target
nonstructur
protein
without
enzymat
function
unknown
host
factor
requir
replic
isol
character
aqresist
mutant
map
mutat
sequenc
analysi
might
reveal
ident
put
viral
target
although
infect
cell
die
within
day
presenc
aq
unpublish
result
longer
incub
period
day
might
yield
escap
mutant
teramoto
et
al
vitro
rdrp
system
ackermann
padmanabhan
nomaguchi
et
al
could
provid
insight
whether
replic
initi
factor
viral
replic
target
aq
studi
provid
evid
anoth
antimalari
compound
cq
inhibit
infect
ec
consist
result
report
previou
studi
faria
et
al
studi
faria
et
al
maximum
inhibitori
effect
seen
h
incub
whether
cq
ad
h
infect
addit
cq
replenish
h
h
initi
addit
h
inhibitori
effect
cq
past
entri
fusion
event
well
translat
initi
replic
phase
moreov
studi
provid
evid
show
profil
inhibit
denv
cq
similar
aq
fig
effect
aq
lost
ad
h
postinfect
fig
cq
seem
divers
antivir
effect
depend
viru
exampl
infect
primari
establish
monocyt
chq
seem
inhibit
entri
product
steadi
state
level
mrna
affect
product
virion
sperber
et
al
cq
report
increas
intracellular
ph
interfer
prm
cleavag
virion
matur
step
life
cycl
concentr
use
studi
randolph
et
al
cq
therapeut
applic
exampl
cq
use
random
control
clinic
studi
treatment
dengu
vietnames
adult
tricou
et
al
cq
also
antivir
activ
solomon
lee
sperber
et
al
sar
coronaviru
de
clercq
vincent
et
al
well
treatment
cancer
arthrit
diseas
moreov
ferroquin
fq
cq
deriv
structur
similar
aq
inhibit
hcv
infect
earli
step
interf
fusion
vausselin
et
al
minor
inhibitori
effect
viral
replic
assembl
current
avail
data
conclud
quinolin
compound
interfer
differ
stage
flavivir
life
cycl
studi
requir
identifi
target
precis
step
target
aq
well
deriv
drug
least
cytotox
treatment
denv
infect
patient
popul
refer
web
version
pubm
central
supplementari
materi
type
nonstructur
protein
interact
rnadepend
rna
polymeras
cell
wash
pb
incub
ml
mainten
medium
aq
dmso
dmso
alon
ad
incub
continu
supernat
sampl
h
postinfect
infect
analyz
plaqu
assay
c
measur
aq
inhibit
infect
direct
plaqu
assay
cell
cell
ml
seed
plate
aq
final
concentr
dmso
ad
moi
